ClinicalTrials.gg
TerminatedNCT03777124Updated Jul 4, 2025

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

A Phase 2 interventional study of SHR-1210 and Apatinib in NSCLC Stage IV, KRAS Gene Mutation and PD-1 Antibody, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Terminated at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-07-04.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Why this study was terminated
The sponsor's R\&D strategy is adjusted.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung — 6 open to participants now, 7 under way, 1 of them phase 3. camrelizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
25th of 27
25 · median 58
Started
2019
with 4 others
Phase 2
17 of 27
4 open now
Registered
6th of 27
by date
Lead sponsor
7 of 27
Jiangsu HengRui Medicine Co., Ltd.

Among the 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 25th largest by enrollment, is one of 5 that started in 2019, is one of 17 in phase 2, and was the 6th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a randomized, open-label, multi-center, phase II trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus Pemetrexed and Carboplatin in Subjects with KRAS mutant stage IV non-squamous Non-small Cell Lung Cancer

03

Conditions studied

  • NSCLC Stage IV
  • KRAS Gene Mutation
  • PD-1 Antibody
  • Chemotherapy Effect
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with histopathological diagnosis of adenocarcinoma non-small cell lung cancer (NSCLC) and clinical stage IV
  2. has not received prior systemic treatment for NSCLC.
  3. Has a performance status of 0 or 1 on the (ECOG) Performance Status
  4. confirmes by the central laboratory as KRAS gene mutation
  5. Has archived Tumor tissue samples
  6. Subject must have a measurable target lesion based on v1.1 .
  7. Women of childbearing age must undergo a serological pregnancy test within 3 days before the first dose with negative results. Female subjects of reproductive age and male subjects whose spouse is a woman of reproductive age must agree to effective within 180 days after the study period and the last dose of the study drug.
  8. Subjects should be voluntarily participate in clinical studies and should be signed.

Exclusion criteria

Exclusion Criteria:

  1. active and meningeal
  2. uncontrollable tumor-related pain
  3. massive pleural effusion, peritoneal effusion or pericardial effusion which cannot be controlled by repeated drainage;
  4. radiotherapy to lung that is >30 Gy within 24 weeks before the first dose,
  5. imaging (CT or MRI) showed that the tumor invading the large vessels
  6. Known EGFR/ALK mutation.
  7. subjects with any known or suspected diseases
  8. subjects with known or suspected interstitial pneumonia;
  9. Subjects with severe cardiovascular and cerebrovascular diseases
  10. arteriovenous thrombosis events, such as deep vein thrombosis and pulmonary embolism, occurred within 3 months;
  11. female subjects who are pregnant or lactation or who plan to be pregnant during the study period;
  12. positive test;
  13. active
  14. evidence of active TB infection within 1 year before first dose;
  15. severe infection occurred within 4 weeks before the first dose
  16. patients with bleeding symptoms or with obvious bleeding tendency in the first month
  17. subjects who is on systemic immunogenic agents;
  18. a history of severe allergic reactions to other monoclonal antibodies/fusion proteins;
  19. History of severe allergic reactions to carboplatin or pemetrexed or their preventive drugs;
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    SHR-1210 +apatinib

    subject will receive SHR-1210 200mg every 2 weeks, apatinib 250mg every day

    Drug: SHR-1210 · Drug: Apatinib

  • Active comparator
    chemotherapy

    Pemetrexed 500mg/m2, Day 1 of each 21 day, 4 cycles carboplatin AUC 5 on Day 1 of each 21 day, 4 cycles followed by pemetrexed 500mg/m2 until progression Q3W

    Drug: Pemetrexed · Drug: Carboplatin

Interventions

  • Subjects receive SHR-1210 intravenous every 2 weeks

  • Subjects receive Apatinib orally every day

  • Subjects receive Pemetrexed intravenous every 3 weeks

  • subjects receive carboplatin intravenous every 3 weeks

06

What researchers measure

Primary outcomes

  1. Duration of Progression-Free Survival (PFS) as Assessed by the Independent Review Committee Using RECIST v1.1

    PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the Independent Review Committee Using RECIST v1.1 or death from any cause, whichever occurs first. Patients who have not experienced disease progression or death at the time of analysis will be censored at the time of last tumor assessment.

    Time frame: up to approximately 40 months

Secondary outcomes

  1. Duration of Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1

    Time Frame: Baseline until PD or death, whichever occurs first

    Time frame: up to approximately 40 months

  2. Duration of Overall Survival (OS)

    Baseline until death from any cause

    Time frame: up to approximately 40 months

  3. Objective Response Rate (ORR)

    The percentage of patients with CR and PR assessed by investigators according to Recist v 1.1.

    Time frame: up to approximately 40 months

  4. disease control rate (DCR)

    The proportion of patients who have achieved complete response, partial response and Stable disease assessed by investigators according to Recist v 1.1.

    Time frame: up to approximately 40 months

  5. Duration of response (DoR)

    Duration of response (DoR)

    Time frame: up to approximately 40 months

  6. Adverse events (AEs)

    All adverse event/Serious adverse event that occurred during the study period according to CTCAE v 5.0

    Time frame: up to approximately 40 months

07

Study locations

1 site
  • Shanghai Chest Hospital
    Shanghai, Shanghai Municipality 200120, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Jun 2023, 47 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2018
First posted
Dec 17, 2018
StartActual
Jul 11, 2019
Primary completionActual
Jun 29, 2023
CompletionActual
Jun 29, 2023
Last update
Jul 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03777124
Responsible party
Sponsor
First posted
Dec 17, 2018
Start date
Jul 11, 2019
Primary completion
Jun 29, 2023
Completion
Jun 29, 2023
Last update
Jul 4, 2025

Study contacts

Jianjun Zou, MD, PhD
study director · Jiangsu HengRui Medicine Co., Ltd.
Shun Lu, MD, PhD
principal investigator · Jiaotong University,Shanghai chest Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion